BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Immunology and inflammation

  Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble

  Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.

  November 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eye Second Phase III

  After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB are planning a second late-stage trial by the end of the year to support a drug application.

  November 19, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Cell Therapy

  CAR T for Lupus Takes Center Stage at ACR 2024

  Investigational CAR T therapies stole the spotlight at the American College of Rheumatology Convergence as data presented by Bristol Myers Squibb, Kyverna Therapeutics and more highlighted their potential to effectively treat lupus.

  November 19, 2024

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Clinical research

  Merck’s Subcutaneous Keytruda Meets Expectations in Phase III

  Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.

  November 19, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Cardiovascular disease

  Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing

  Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.

  November 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Duchenne muscular dystrophy

  Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies

  Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.

  November 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pipeline

  Neurogene Drops Batten Gene Therapy Program

  After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.

  November 19, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• Press Releases

  EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - November 18, 2024

  November 19, 2024

   · 

  2 min read
• Press Releases

  Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

  November 19, 2024

   · 

  8 min read
• Press Releases

  MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

  November 19, 2024

   · 

  6 min read